Ergomed plc Completion of Acquisition of PSR Group BV (4800S)
03 October 2017 - 5:00PM
UK Regulatory
TIDMERGO
RNS Number : 4800S
Ergomed plc
03 October 2017
Ergomed plc
Completion of Acquisition of PSR Group BV, a specialist orphan
drug CRO
London, UK - 3 October 2017: Ergomed plc (AIM: ERGO) ("Ergomed"
or the "Company"), is pleased to announce that, further to the
Company's announcement on 28 September 2017, the acquisition of PSR
Group BV ("PSR") has completed following the admission to trading
on AIM of the 2,081,389 new ordinary shares of 1p each at 8.00 a.m.
on 2 October 2017.
A total of 1,757,576 new ordinary shares in the Company of 1p
each (the "Placing Shares") were placed at a price of 165p per
Placing Share (the "Placing Price") with new and existing
investors, raising proceeds of GBP2.9m (before expenses) to
part-fund the acquisition of PSR. In addition, a further 323,813
new ordinary shares were issued at a price of 165p per share to PSR
as initial share consideration ("Initial Consideration
Shares").
Following the Admission of the Placing Shares and Initial
Consideration Shares, the Company's issued share capital now
comprises 42,680,813 ordinary shares of 1p each. The above figure
may be used by Shareholders as the denominator for the calculations
by which they will determine whether they are required to notify
their interest in, or a change to their interest in, the Company
under the Financial Conduct Authority's Disclosure and Transparency
Rules.
Enquiries:
Ergomed plc Tel: +44 (0)
1483 503205
Dan Weng (Chief Executive Officer)
Stephen Stamp (Chief Financial
Officer)
Numis Securities Limited Tel: +44 (0)
20 7260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black (Joint Broker)
N+1 Singer Tel: +44 (0)
20 7496 3000
Alex Price (Joint Broker)
Michael Taylor
Consilium Strategic Communications Tel: +44 (0)
- for UK enquiries 20 3709 5700
Chris Gardner / Mary-Jane ergomed@consiliumcomms.com
Elliott
Ivar Milligan / Philippa Gardner
MC Services - for Continental Tel: +49 211
European enquiries 5292 5222
Anne Hennecke
About Ergomed
Ergomed provides specialist services to the pharmaceutical
industry and develops drugs both wholly-owned and through
partnerships. Ergomed's fast-growing, profitable service offering
spans all phases of clinical development and post-approval
pharmacovigilance and medical information. Drawing on more than 20
years of expertise in drug development, Ergomed is also building a
growing portfolio of drug development partnerships and programmes,
including wholly-owned proprietary products for the treatment of
surgical bleeding. For further information, visit:
http://ergomedplc.com
About PSR
PSR, established in 1998, is a full service specialist orphan
drug CRO and recognised as a leading expert in the rare disease
niche. PSR specialises in running complex orphan drug development
programs requiring innovative regulatory and clinical approaches as
well as pricing and reimbursement strategies. Besides outsourced
project solutions, PSR provides insourced staffing solutions
(orphan drug teams), temporary & permanent staffing, interim
management solutions as well as training / coaching career
programs.
PSR's dedication to the rare disease landscape is exemplified by
an extensive track record of orphan drug projects in a wide range
of therapeutic areas, its continued efforts to achieve true patient
centricity and its societal commitments by participation in
fundraising activities and public-private partnerships. For
further
information, visit: http://www.psr-group.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACQOKBDQABDDPKK
(END) Dow Jones Newswires
October 03, 2017 02:00 ET (06:00 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024